ACA

;

71 patient groups comment on the NBPP for 2024 proposed rule

Jan 30, 2023

We, the undersigned 71 organizations, on behalf of millions of patients and American consumers who live with complex conditions such as HIV, autoimmune diseases, cancer, diabetes, lupus, hemophilia, mental illness, hepatitis, neurological diseases, and other chronic illnesses, write to comment on the Notice of Benefits and Payment Parameters for 2024 Proposed Rule.  The patients we represent appreciate all you are doing to make healthcare more accessible and affordable for beneficiaries. While there are several components of the Proposed Rule that many of us will comment on elsewhere, this letter focuses on those issues that impact access and affordability of prescription drugs.

read more

Comments on the USPSTF draft research plan “Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis”

Dec 6, 2021

We urge the USPSTF to consider the following two recommendations as it finalizes its plan “Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis”: research should explicitly evaluate and describe the ancillary services that are integral to the PrEP intervention and the USPSTF should adopt a more nimble and timely review of the PrEP recommendation as new products see clinical trial success.

read more

Comments on draft hepatitis federal implementation plan

Nov 19, 2021

We cannot achieve the goal of ending hepatitis without increased funding for the key elements of the strategy, including testing, treating, and vaccination. Increasing resources for hepatitis elimination must be our first priority. While this draft hepatitis federal implementation plan was drafted with current resources in mind, there are areas where we would suggest some strengthening.

read more

Letter in support of improving patient drug affordability through standardized benefit plans

Jul 28, 2021

We, the undersigned 40 organizations, on behalf of millions of patients and American consumers who live with complex conditions such as HIV, autoimmune diseases, cancer, diabetes, lupus, hemophilia, and hepatitis, write in response to the request for comments on the proposed rule that would amend the 2022 payment and parameters rule. The patients we represent appreciate all you are doing to make healthcare more accessible and affordable for beneficiaries. There are many aspects of the proposed rule that we support; however, one issue that we would like to focus on is your desire to offer standardized options for qualified health plans beginning in 2023.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest